Dexcom, Inc. DXCM

Revenue Intelligence Report • 62 quarters of SEC filing data • Updated 2026-03-15

Dexcom, Inc. has a forecasted full-year revenue of $5.6B, a +20.2% year-over-year change, based on 62 quarters of SEC filing data. The ARDL model has 5.5% MAPE.

Investment Thesis

The econometric model achieves strong accuracy (5.5% MAPE), suggesting Dexcom, Inc.'s revenue trajectory is well-characterized by its spending patterns. R&D spending currently shows a negative elasticity (-0.88x), which can indicate heavy investment in long-cycle initiatives not yet reflected in revenue.

Next FY Revenue
$5.60B
+20.2% YoY
R&D Elasticity
-0.88x
SG&A Elasticity
-0.32x
Model Accuracy
5.5% MAPE
Holdout validation: The model predicted $1.3B vs the actual $1.3B — an error of 2.9%.
⚠ Model limitation: This company shows negative spending multipliers, meaning increases in spending have not directly translated into revenue growth. This typically occurs with commodity-driven companies or hypergrowth companies.

Revenue Forecast

DXCM Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $1.3B $1.3B $1.1B – $1.5B +16.4% ✓ In range
Q2 2026 $1.3B $1.1B – $1.6B +24.4%
Q3 2026 $1.4B $1.1B – $1.7B +18.2%
Q4 2026 $1.4B $1.1B – $1.9B +17.5%
Q1 2027 $1.5B $1.1B – $2.1B +21.1%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Dexcom, Inc.'s systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Sep–Nov) 1.0306 +3.1% +3.1% above trend 15
FQ2 (Dec–Feb) 1.0294 +2.9% In line with trend 15
FQ3 (Mar–May) 0.9603 -4.0% -4.0% below trend 14
FQ4 (Jun–Aug) 1.0032 +0.3% In line with trend 14

How Spending Drives Revenue

DXCM Spending Timing
Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

More in Healthcare

WST BDX CNC REGN IQV UNH HOLX ISRG